



International Conference on Reproduction, Pregnancy and Rheumatic diseases

26-28 August 2021

Final Programme



#### **UNDER THE AUSPICES OF**

















#### **WELCOME**

Rheumatic diseases are not rare in the general population and they can affect women and men during their fertile age. Therefore, it is necessary to counsel young patients (both males and females) about their desire to have children. When a woman affected by a rheumatic disease wants a baby, it is necessary to assess and discuss the possible influence of pregnancy on her disease and the impact of her disease on the pregnancy outcome. In addition, information about the use of drugs in male and female patients wishing to conceive and during pregnancy is crucial for an adequate management. However, this information is usually scarce and not derived from clinical trials.

Other issues related to the reproductive journey have emerged as "unmet needs" for rheumatic patients. For instance, there is need for more discussion about contraceptive methods, medically assisted reproduction techniques, breastfeeding, long-term outcome of children, parenting with a chronic disease.

The International Conference will gather not only expert physicians and researchers but also midwives, nurses and other heath professionals from all over the world to discuss and share their data, their experience and to draft future collaborative studies. Although the increasing research efforts in the field, the highest level of evidence-based medicine cannot be applied in every area of the reproductive field. Therefore, it becomes crucial to foster a scientific community who is in charge of developing recommendations for patients' management based on both published evidence and expert opinion.

Prof. Angela Tincani Chairperson of the Meeting

#### **COMMITTEES**

#### CHAIRPERSON OF THE MEETING

Angela Tincani

#### INTERNATIONAL SCIENTIFIC COMMITTEE

Christina Chambers

Megan Clowse

Nathalie Costedoat-Chalumeau

Radboud J.E.M.Dolhain

Frauke Förger

Munther Khamashta

Roger A. Levy

Catherine Nelson-Piercy

Luigi Raio

Guillermo Ruiz-Irastorza

Yehuda Shoenfeld

Peter M. Villiger

Marie Wahren-Herlenius

Marianne Wallenius

#### SCIENTIFIC SECRETARIAT

Laura Andreoli

Angela Botta

Cecilia Chighizola

Maria Gerosa

Luca laccarino

Véronique L. Ramoni

Chiara Tani

#### LOCAL SCIENTIFIC COMMITTEE

Antonio L. Brucato

Roberto Caporali

Irene Cetin

Maurizio Cutolo

Sara De Carolis

Andrea Doria

Enrico Ferrazzi

Marcello Govoni

Elisa Gremese

Florenzo lannone

Andrea Lojacono

Marco Matucci Cerinic

Pier Luigi Meroni

Marta Mosca

Carlo Salvarani

Gian Domenico Sebastiani



#### **THURSDAY 26 AUGUST 2021**

	BACCARAT ROOM	AZALEA ROOM
13:45-14:00	Welcome Message	
14:00-15:30	Working groups on pregnancy in rheumatic diseases: updates about the projects	
15:30-16:00	Break	
16:00-17:30	Pregnancy planning	Curbside consultation 1
17:30-19:00	INDUSTRY-SPONSORED SYMPOSIUM	
19:00-19:30	OPENING CEREMONY	

#### **LEGENDA**

CONGRESS SESSIONS AND ORAL PRESENTATIONS	INDUSTRY-SPONSORED SYMPOSIUM	MEET THE PROFESSOR
--	---------------------------------	--------------------



Schedules refer to the Central European Time Zone (GMT+1)

#### FRIDAY 27 AUGUST 2021

	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM 5
	NO	NO	NO	NO	NO
07:30-08:15	Meet the Professor: Antiphospholipid antibody syndrome	Meet the Professor: Treatment of chronic arthritis	Meet the Professor: Systemic lupus erythematosus	Meet the Professor: Safety of antirheumatic drugs	Meet the Professor: Counseling about reproduction issue in Rheumatology

	BACCARAT ROOM	AZALEA ROOM
08:30-10:00	Rheumatic diseases and pregnancy	Hormones immunity and rheumatic diseases
10:00-10:30	Break	
10:30-12:00	Rare rheumatic diseases and pregnancy	Curbside consultation 2
12:00-12:45	1 - The great debate	2 - The great debate
12:45-14:30	Lunch break	
14:30-16:00	Antirheumatic drugs in pregnancy	
16:00-16:30	Break	
16:30-18:00	Predictors of adverse pregnancy outcome	Curbside consultation 3

#### **LEGENDA**



**Schedules refer to the Central European Time Zone (GMT+1)** 



#### **SATURDAY 28 AUGUST 2021**

	BACCARAT ROOM	AZALEA ROOM
08:30-10:00	The experience of registries	General management of pregnant women with rheumatic diseases
10:00-10:30	Break	
10:30-12:00	When the baby is born	
12:00-12:30	CLOSING CEREMONY	

#### **LEGENDA**

CONGRESS SESSIONS AND ORAL PRESENTATIONS	INDUSTRY-SPONSORED SYMPOSIUM	MEET THE PROFESSOR
--	---------------------------------	--------------------



Schedules refer to the Central European Time Zone (GMT+1)

#### **THURSDAY 26 AUGUST 2021**

#### **Baccarat Room**

#### 13:45-14:00 WELCOME MESSAGE

F. Förger (Bern, Switzerland), A. Tincani (Brescia, Italy)

#### **Baccarat Room**

### 14:00-15:30 WORKING GROUPS ON PREGNANCY IN RHEUMATIC DISEASES: UPDATES ABOUT THE PROJECTS

Chairperson: A. Tincani (Brescia, Italy)

Working Group 1 - Benefits and challenges of the counselling about reproduction in patients with rheumatic diseases

F. Förger (Bern, Switzerland)

Working Group 2 - Hot topics in reproductive rheumatology C. Nelson-Piercy (London, UK)

Working Group 3 - Reproductive issues in rare rheumatic diseases M. Mosca (Pisa, Italy), C. Tani (Pisa, Italy), D. Marinello (Pisa, Italy)

15:30-16:00 Break

#### **Baccarat Room**

#### 16:00-17:30 PREGNANCY PLANNING

Chairpersons: B. Bermas (Dallas, USA), E. Ferrazzi (Milan, Italy)

Sexuality in patients with rheumatic diseases

C. Zanardini (Brescia, Italy)

How to select contraception methods in women with rheumatic diseases E. Chakravarty (Oklahoma City, USA)

**Drug treatment in men affected by rheumatic diseases who want to conceive** I. Giles (London, UK)

BARRIERS TO SHARED DECISION-MAKING WITH WOMEN OF REPRODUCTIVE AGE AFFECTED BY RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR AXIAL SPONDYLOARTHRITIS

S. Murray<sup>1</sup>, C. Nelson-Piercy<sup>2</sup>, M. Augustyniak<sup>1</sup>, R. Fischer-Betz<sup>3</sup>, J. Murase<sup>4,5</sup>, I. Vlaev<sup>6</sup>, C. Ecoffet<sup>7</sup>, M. Peniuta<sup>1</sup>, D. Jenkins<sup>8</sup>

(<sup>1</sup>Brossard, Canada, <sup>2</sup>London, UK, <sup>3</sup>Düsseldorf, Germany, <sup>4</sup>San Francisco, USA, <sup>5</sup>Palo Alto, USA, <sup>6</sup>Warwick, UK, <sup>7</sup>Brussels, Belgium, <sup>8</sup>Truro, UK)

#### **THURSDAY 26 AUGUST 2021**

### HOW TO COUNSEL A WOMAN WITH BEHÇET'S DISEASE: RESULTS FROM A MONOCENTRIC COHORT OF WOMEN DIAGNOSED DURING CHILDBEARING AGE

S. Sciascia<sup>1</sup>, M. Radin<sup>1</sup>, I. Cecchi<sup>1</sup>, E. Rubini<sup>1</sup>, K. Schreiber<sup>2</sup>, D. Rossi<sup>1</sup>, D. Roccatello<sup>1</sup> (<sup>1</sup>Turin, Italy, <sup>2</sup>Sønderborg, Denmark)

### IMPACT OF PSORIATIC ARTHRITIS ON FAMILY PLANNING AND PREGNANCY IN WOMEN AGED 18–45: RESULTS FROM A SURVEY ACROSS 11 EUROPEAN COUNTRIES

L. Andreoli<sup>1</sup>, C. De Simone<sup>2</sup>, L. Catton<sup>3</sup>, L. Senturk<sup>4</sup>, C. Ecoffet<sup>4</sup>, J. Koren<sup>5</sup>, A. Titialii<sup>6</sup> (<sup>1</sup>Brescia, Italy, <sup>2</sup>Rome, Italy, <sup>3</sup>Slough, UK, <sup>4</sup>Brussels, Belgium, <sup>5</sup>Polzela, Slovenia, <sup>6</sup>Stockholm. Sweden)

#### Azalea Room

#### 16:00-17:30 CURBSIDE CONSULTATION 1

Chairpersons: G.D. Sebastiani (Rome, Italy), V. Smith (Ghent, Belgium)

#### Counselling a patient with previous miscarriages

Presenter: L. Andreoli (Brescia, Italy)

Discussants:

W. Marder (Ann Arbor, USA), P.L. Meroni (Milan, Italy), C. Nelson-Piercy (London, UK)

#### Medically assisted reproductive techniques

Presenter: C. Tani (Pisa, Italy)

Discussants:

F. Ceccarelli (Rome, Italy), N. Costedoat-Chalumeau (Paris, France).

P. Rovere Querini (Milan, Italy)

#### Obstetric ultrasound monitoring in anti-Ro positive patients

Presenter: M. Fredi (Brescia, Italy)

Discussants:

A.L. Brucato (Milan, Italy), J. Buyon (New York, USA), L. Raio (Bern, Switzerland)

#### **Baccarat Room**

17:30-19:00 INDUSTRY-SPONSORED SYMPOSIUM (see page 37)

#### **Baccarat Room**

#### 19:00-19:30 OPENING CEREMONY

### WHY WE DEVELOP AUTOIMMUNE DISEASES AND HOW IT IMPLICATES THE REPRODUCTION AND PREGNANCY

Chairpersons: L. Sinigaglia (Milan, Italy), A. Tincani (Brescia, Italy) Speaker: Y. Shoenfeld (Tel Aviv, Israel)



#### FRIDAY 27 AUGUST 2021

Room 1

07:30-08:15 MEET THE PROFESSOR:



Antiphospholipid antibody syndrome

M. Khamashta (Dubai, UAE)

Room 2

07:30-08:15 MEET THE PROFESSOR:



Treatment of chronic arthritis

F. Förger (Bern, Switzerland)

Room 3

07:30-08:15 **MEET THE PROFESSOR:** 



**Systemic lupus erythematosus** M. Clowse (Durham, USA)

Room 4

07:30-08:15 MEET THE PROFESSOR:



Safety of antirheumatic drugs C. Chambers (San Diego, USA)

Room 5

07:30-08:15 **MEET THE PROFESSOR**:



Counseling about reproduction issue in Rheumatology R. Caporali (Milan, Italy)

#### **FRIDAY 27 AUGUST 2021**

**Baccarat Room** 

#### 08:30-10:00 RHEUMATIC DISEASES AND PREGNANCY

Chairpersons: N. Costedoat-Chalumeau (Paris, France), A. Doria (Padua, Italy)

#### Interaction between pregnancy and chronic arthritis

F. Förger (Bern, Switzerland)

Pregnancy in patients with systemic lupus erythematosus: what is changing J. Salmon (New York, USA)

### Pregnancy in patients with antiphospholipid antibodies: how to prevent pregnancy loss

M. Khamashta (Dubai, UAE)

## A TREAT-TO-TARGET APPROACH INCLUDING THE USE OF TNF-INHIBITORS RESULTS IN LOW DISEASE ACTIVITY IN 90% OF PREGNANT RHEUMATOID ARTHRITIS PATIENTS, FIRST RESULTS OF THE PRECARA COHORT

J. Smeele, E Röder, H. Wintjes, L.J.C. Kranenburg, J.M.W. Hazes, R.J.E.M. Dolhain (Rotterdam, The Netherlands)

## PREDICTIVE FACTORS FOR DISTINCT ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTERED RETROSPECTIVE COHORT STUDY

L. Liu, J. Zhao, Q. Wang, X. Tian, M. Li, X. Zeng (Beijing, China)

## ANTI-SSA/RO POSITIVITY AND CONGENITAL HEART BLOCK: OBSTETRIC AND FETAL OUTCOME IN A COHORT OF ANTI-SSA/RO POSITIVE PREGNANT WOMEN WITH AND WITHOUT AUTO-IMMUNE DISEASES FROM THREE ITALIAN TERTIARY REFERRAL CENTERS

M. Gerosa<sup>1</sup>, M. Fredi<sup>2</sup>, L. Andreoli<sup>2</sup>, C.B. Chighizola<sup>1</sup>, L. Argolini<sup>1</sup>, V.L. Ramoni<sup>4</sup>, C. Montecucco<sup>3</sup>, L. Trespidi<sup>1</sup>, F. Gazzola<sup>1</sup>, T. Vojinovic<sup>2</sup>, S. Zatti<sup>2</sup>, E. Ferrazzi<sup>1</sup>, P.L. Meroni<sup>1</sup>, R. Cimaz<sup>1</sup>, R. Caporali<sup>1</sup>, A. Tincani<sup>2</sup> (<sup>1</sup>Milan, Italy, <sup>2</sup>Brescia, Italy, <sup>3</sup>Pavia, Italy, <sup>4</sup>Lodi, Italy)

10:00-10:30 Break

#### **FRIDAY 27 AUGUST 2021**

Azalea Room

#### 08:30-10:00 HORMONES, IMMUNITY AND RHEUMATIC DISEASES

Chairpersons: I. Cetin (Milan, Italy), P.M. Villiger (Bern, Switzerland)

#### Sex hormones in rheumatic diseases

M. Cutolo (Genoa, Italy)

#### Immunology of pregnancy

P.L. Meroni (Milan, Italy)

#### Women with rheumatic diseases: fertile, sub-fertile or in-fertile

R.J.E.M. Dolhain (Rotterdam, The Netherlands)

### THE TIP OF AN ICEBERG: ENDOMETRIOSIS AND MENSTRUAL RELATED PAIN IN RHEUMATIC DISEASES (RDS)

M. Orlandi, S. Vannuccini, K. El Aoufy, M.R. Melis, S. Bellando Randone, S. Guiducci, M. Matucci Cerinic, F. Petraglia (Florence, Italy)

#### FERTILITY AND SEXUAL LIFE IN WOMEN WITH SJÖGREN'S SYNDROME

F. Giardina, I. Merlino, E. Ciminello, M. De Roma, V. Del Negro, M. Porpora, E. Anastasi, S. Tartaglione, F. Conti, R. Priori, M. Piccioni (Rome, Italy)

## DISEASE ACTIVITY IN PREGNANT WOMEN WITH RHEUMATOID ARTHRITIS: IMPACT ON THE SOLUBLE FMS-LIKE TYROSINE KINASE-1 TO PLACENTAL GROWTH FACTOR RATIO

J. Smeele, R.I. Neuman, A.H.J. Danser, R.J.E.M. Dolhain, W. Visser (Rotterdam, The Netherlands)

#### **FRIDAY 27 AUGUST 2021**

**Baccarat Room** 

#### 10:30-12:00 RARE RHEUMATIC DISEASES AND PREGNANCY

Chairpersons: M. Matucci Cerinic (Florence, Italy), P.L. Meroni (Milan, Italy)

#### Systemic sclerosis patients in pregnancy

A.L. Brucato (Milan, Italy), E. Tombetti (Milan, Italy)

#### Takayasu arteritis

P.M. Villiger (Bern, Switzerland)

#### Other rare rheumatic diseases in pregnancy

M. Mosca (Pisa, Italy)

### INTERNATIONAL MULTICENTRIC PROSPECTIVE STUDY ON PREGNANCY IN SYSTEMIC SCLEROSIS (IMPRESS-2)

E. Tombetti<sup>1</sup>, V.L. Ramoni<sup>2</sup>, M. Betelli<sup>3</sup>, Y. Allanore<sup>4</sup>, M. Matucci Cerinic<sup>5</sup>, A. Tincani<sup>6</sup>, A.L. Brucato<sup>1,3</sup>, on behalf of the IMPRESS-2 Study Group (<sup>1</sup>Milan, Italy, <sup>2</sup>Lodi, Italy, <sup>3</sup>Bergamo, Italy, <sup>4</sup>Paris, France, <sup>5</sup>Florence, Italy, <sup>6</sup>Brescia, Italy)

#### PREGNANCY OUTCOMES IN PATIENTS WITH INTERSTITIAL LUNG DISEASE

A. Rajendran<sup>1</sup>, A. Eudy<sup>1</sup>, S. Giattino<sup>2</sup>, A. Swaminathan<sup>1</sup>, M. Clowse<sup>1</sup> (\*Durham, USA, \*Wynnewood, USA)

## CAN SYSTEMIC SCLEROSIS BE A CONCERN FOR PREGNANCY AS SYSTEMIC LUPUS ERITHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME? A RETROSPECTIVE STUDY.

G. Barilaro, A.S. Castellanos, I. da Cunha Texeira Gomes F., A.I. Rebollo Gimenez, G. Levon, N. Baños Lopez, F. Figueras, G. Espinosa (Barcelona, Spain)

#### **FRIDAY 27 AUGUST 2021**

#### Azalea Room

#### 10:30-12:00 CURBSIDE CONSULTATION 2

Chairpersons: R. Caporali (Milan, Italy), S. De Carolis (Rome, Italy)

#### Changing treatment before and during pregnancy in rheumatoid arthritis

Presenter: V.L. Ramoni (Lodi, Italy)

Discussants:

M. Clowse (Durham, USA), R.J.E.M. Dolhain (Rotterdam, The Netherlands),

F. Förger (Bern, Switzerland)

#### Fertility in psoriatic arthritis

Presenter: M.S. Chimenti (Rome, Italy)

Discussants:

C. De Simone (Rome, Italy), I. Giles (London, UK), M. Wallenius (Trondheim, Norway)

#### How to counsel a patient with juvenile rheumatoid arthritis

Presenter: M. Gerosa (Milan, Italy)

Discussants:

M. Cattalini (Brescia, Italy), I. Haase (Düsseldorf, Germany), L. Moore (Dublin, Ireland)

#### **Baccarat Room**

#### 12:00-12:45 1- THE GREAT DEBATE

Chairpersons: A.L. Brucato (Milan, Italy), F. Franceschini (Brescia, Italy)

#### Pregnant patients with anti-Ro/SSA: intensive surveillance or not?

N. Costedoat-Chalumeau (Paris, France) vs M. Wahren-Herlenius (Stockholm, Sweden)

#### Azalea Room

#### 12:00-12:45 2- THE GREAT DEBATE

Chairpersons: L. Raio (Bern, Switzerland), Y. Shoenfeld (Tel Aviv, Israel)

#### Non criteria obstetric APS: to treat or not to treat?

C.B. Chighizola (Milan, Italy) vs R.A. Levy (Rio de Janeiro, Brazil)

12:45-14:30 Lunch Break

#### **FRIDAY 27 AUGUST 2021**

**Baccarat Room** 

#### 14:30-16:00 ANTIRHEUMATIC DRUGS IN PREGNANCY

Chairpersons: A. Doria (Padova, Italy), R.A. Levy (Rio de Janeiro, Brazil)

### Risk/safety/effectiveness of medication in pregnant patients with rheumatic diseases

C. Chambers (San Diego, USA)

#### New biologics, biosimilars and small molecules: where we are

C. Nelson-Piercy (London, UK)

**Maternal infections and vaccinations in pregnant patients with rheumatic diseases** S. De Carolis (Rome, Italy)

### PHARMACOVIGILANCE PREGNANCY DATA IN A LARGE POPULATION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASE EXPOSED TO CERTOLIZUMAB PEGOL

M. Clowse<sup>1</sup>, R. Fischer-Betz<sup>2</sup>, T. Kumke<sup>3</sup>, B. Lauwerys<sup>4</sup>, R. Kasliwal<sup>5</sup>, F. Förger<sup>6</sup> (<sup>1</sup>Durham, USA, <sup>2</sup>Düsseldorf, Germany, <sup>3</sup>Monheim am Rhein, Germany, <sup>4</sup>Brussels, Belgium, <sup>5</sup>Slough, UK, <sup>6</sup>Bern, Switzerland)

### PREGNANCY IN SLE PATIENTS TREATED WITH BELIMUMAB: EXPERIENCE FROM 3 ITALIAN CENTERS

F. Crisafulli<sup>1</sup>, M.C. Gerardi<sup>1</sup>, L. Moschetti<sup>1</sup>, M. Fredi<sup>1</sup>, C. Nalli<sup>1</sup>, M.L. Urban<sup>2</sup>, G. Emmi<sup>2</sup>, F. Saccon<sup>3</sup>, M. Zen<sup>3</sup>, L. Iaccarino<sup>3</sup>, A. Doria<sup>3</sup>, F. Franceschini<sup>1</sup>, L. Andreoli<sup>1</sup>, A. Tincani<sup>1</sup> (\*Brescia, Italy, \*Florence, Italy, \*Padua, Italy)

## TREATMENT PATTERNS AND DISEASE FLARES OF PREGNANT WOMEN WITH INFLAMMATORY RHEUMATIC DISEASES IN GERMANY: A CLAIMS DATABASE ANALYSIS

R. Fischer-Betz<sup>1</sup>, W. Dombrowsky<sup>2</sup>, L. Joeres<sup>2</sup>, T. Heidbrede<sup>2</sup>, K. Blaschke<sup>3</sup> (<sup>1</sup>Düsseldorf, Germany, <sup>2</sup>Monheim am Rhein, Germany, <sup>3</sup>Cologne, Germany)

#### FRIDAY 27 AUGUST 2021

Azalea Room

#### 14:30-16:00 ORAL COMMUNICATIONS: MISCELLANEA

Chairpersons: L. Andreoli (Brescia, Italy), A. Botta (Rome, Italy)

## MEN DIAGNOSED WITH INFLAMMATORY ARTHRITIS BEFORE THE AGE OF 40 YEARS HAVE A LOWER FERTILITY RATE THAN THOSE DIAGNOSED AFTER THE AGE OF 40 YEARS: RESULTS OF A LARGE MULTICENTER STUDY (IFAME-FERTILITY)

L.F. Perez¹, E. Röder¹, H. Smeele¹, I. Tchetverikov², P. Veldt-Kok³, J. Van Der Kaap⁴, M. Kok¹, A. Van Der Helm-Van Mil⁵, Y. Ruiterman⁶, J. Hazes¹, B. Krijthe¹, R.J.E.M. Dolhain¹ (¹Rotterdam, The Netherlands, ²Dordrecht, The Netherlands, ³Delft, The Netherlands, ⁴Goes, The Netherlands, ⁵Leiden, The Netherlands, ⁵Den Haaq, The Netherlands)

## NEUROPSYCHIATRIC OUTCOME OF CHILDREN BORN TO WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND EXPOSED IN UTERO TO AZATHIOPRINE: A CASE-CONTROL STUDY FROM TWO ITALIAN CENTRES

M.G. Lazzaroni<sup>1</sup>, L. Andreoli<sup>1</sup>, F. Crisafulli<sup>1</sup>, F. Tamborini<sup>2</sup>, I. Debeni<sup>1</sup>, V. Binda<sup>2</sup>, C. Nalli<sup>1</sup>, J. Galli<sup>1</sup>, E. Fazzi<sup>1</sup>, G. Moroni<sup>2</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup> (\*Brescia, Italy, \*2Milan, Italy)

## IMPACT OF THE NEW 2019 EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN A MULTICENTER COHORT STUDY OF 133 WOMEN EVER PREGNANT WITH UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE

M. Radin<sup>1</sup>, K. Schreiber<sup>2</sup>, I. Cecchi<sup>1</sup>, A. Bortoluzzi<sup>3</sup>, F. Crisafulli<sup>4</sup>, C. De Freitas<sup>5</sup>, B. Bacco<sup>1</sup>, E. Rubini<sup>1</sup>, S. Foddai<sup>1</sup>, M. Padovan<sup>3</sup>, S. Gallo Cassarino<sup>1</sup>, F. Franceschini<sup>4</sup>, D. Andrade<sup>5</sup>, C. Benedetto<sup>1</sup>, M. Govoni<sup>3</sup>, T. Bertero<sup>1</sup>, L. Marozio<sup>1</sup>, D. Roccatello<sup>1</sup>, L. Andreoli<sup>4</sup>, S. Sciascia<sup>1</sup> (<sup>1</sup>Turin, Italy, <sup>2</sup>Copenhagen, Denmark, <sup>3</sup>Ferrara, Italy, <sup>4</sup>Brescia, Italy, <sup>5</sup>Sao Paolo, Brazil)

#### SEXUAL AND REPRODUCTIVE HEALTH IN WOMEN WITH SYSTEMIC SCLEROSIS

B. Hermankova, M. Spiritovic, H. Smucrova, S. Oreska, S. Hana, P. Karel, V. Jiri, S. Ladislav, B. Radim, T. Michal (*Prague, Czech Republic*)

### EXPLORING THE SEXUAL AND REPRODUCTIVE HEALTH EXPERIENCES OF MALE PATIENTS WITH RHEUMATIC DISEASES

O. Stransky, N. Hunt, M. Birru Talabi (*Pittsburgh, USA*)

#### **FRIDAY 27 AUGUST 2021**

## HISTOPATHOLOGICAL PLACENTA FINDINGS FROM PATIENTS WITH ADVERSE PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS, ANTIPHOSPHOLIPID SYNDROME OR NON-CRITERIA OBSTETRIC ANTIPHOSPHOLIPID SYNDROME

A.S. Castellanos Gutierrez , G. Espinosa, F. Figueras, M. Santana, N. Baños (Barcelona, Spain)

## PREGNANCY OUTCOME AND IMPACT ON DISEASE ACTIVITY IN YOUNG WOMEN AFFECTED BY JUVENIL IDIOPATHIC ARTHRITIS (JIA): A MONOCENTRIC EXPERIENCE IN A TERTIARY CENTRE IN MILAN

L.M. Argolini, M. Gerosa, I. Pontikaki, F. Luppino, L. Trespidi, M.W. Ossola, E. Ferrazzi, R. Cimaz, R. Caporali (*Milan, Italy*)

### OUTCOME AND TREATMENT OF VILLITIS OF UNKNOWN ORIGIN: SYSTEMATIC LITERATURE REVIEW

A. Mekinian, N. Abisror, O. Fain (Paris, France)

### THE RISK OF DEPRESSIVE SYMPTOMS AND POSTPARTUM DEPRESSION AMONG WOMEN WITH RHEUMATIC DISEASES: DATA FROM THE P-RHEUM.IT STUDY

F. Crisafulli<sup>1</sup>, M.C. Gerardi<sup>1</sup>, A. Zanetti<sup>2</sup>, G. Carrara<sup>2</sup>, A. Bortoluzzi<sup>2,3</sup>, M. Filippini<sup>1</sup>, M. Fredi<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, D. Lini<sup>1</sup>, L. Moschetti<sup>1</sup>, S. Panaro<sup>1</sup>, F. Regola<sup>1</sup>, C. Nalli<sup>1</sup>, M. Taglietti<sup>1</sup>, A. Lojacono<sup>1</sup>, S. Zatti<sup>1</sup>, F. Ramazzotto<sup>1</sup>, C.A. Scirè<sup>2,3</sup>, L. Andreoli<sup>1</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup> (<sup>1</sup>Brescia, Italy, <sup>2</sup>Milan, Italy, <sup>3</sup>Ferrara, Italy)

16:00-16:30 Break

#### Baccarat Room

#### 16:30-18:00 PREDICTORS OF ADVERSE PREGNANCY OUTCOME

Chairpersons: M. Birru-Talabi (Pittsburgh, USA), P.L. Meroni (Milan, Italy)

#### Biomarkers in SLE pregnancy

J. Buyon (New York, USA)

### Predictors of preeclampsia and obstetric complications in patients with rheumatic diseases

L. Raio (Bern, Switzerland)

#### Pregnancy outcome in patients with active rheumatic disease

I. Cetin (Milan, Italy)

#### FRIDAY 27 AUGUST 2021

ADVERSE PREGNANCY OUTCOMES IN RELATION TO DISEASE ACTIVITY AND ANTI-RHEUMATIC TREATMENT STRATEGIES IN WOMEN WITH RHEUMATOID ARTHRITIS - A COLLABORATIVE MATCHED COHORT STUDY FROM SWEDEN AND DENMARK

K. Hellgren<sup>1</sup>, A.E. Secher<sup>2</sup>, B. Glintborg<sup>2</sup>, A. Lillehoren Rom<sup>2</sup>, B. Gudbjornsson<sup>3</sup>, B. Michelsen<sup>4</sup>, F.Granath<sup>1</sup>, M. Lund Hetland<sup>2</sup> (\*Stockholm, Sweden, \*Copenhagen, Denmark, \*Reykjavik, Iceland, \*Oslo, Norway)

MONITORING C3 AND C4 VARIATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES IS USEFUL TO RECOGNIZE COMPLICATIONS. DATA FROM 2 ITALIAN CENTERS.

F. Crisafulli<sup>1</sup>, L. Andreoli<sup>1</sup>, M. Filippini<sup>1</sup>, M. Fredi<sup>1</sup>, M.C. Gerardi<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup> D. Lini<sup>1</sup>, C. Nalli<sup>1</sup>, M. Taglietti<sup>1</sup>, A. Lojacono<sup>1</sup>, S. Zatti<sup>1</sup>, C. Zanardini<sup>1</sup>, C. Tani<sup>2</sup>, D. Zucchi<sup>2</sup>, M. Mosca<sup>2</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup> (\*Brescia, Italy, \*Pisa, Italy)

### EFFECT OF ACTIVE LUPUS NEPHRITIS ON PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS

A. Eudy<sup>1</sup>, A. Lucas<sup>1</sup>, S. Balevic<sup>1</sup>, M. Petri<sup>2</sup>, D. Gladman<sup>3</sup>, M. Urowitz<sup>3</sup>, M. Clowse<sup>1</sup> (\*Durham, USA, \*Baltimore, USA, \*Toronto, Canada)

#### Azalea Room

#### 16:30-18:00 CURBSIDE CONSULTATION 3

Chairpersons: F. lannone (Bari, Italy), C. Nelson-Piercy (London, UK)

#### Thyroid diseases in rheumatic pregnancies

Presenter: A. Botta (Rome, Italy)

Discussants:

G. De Jesús (Rio de Janeiro, Brazil), Y. Shoenfeld (Tel Aviv, Israel), C. Zanardini (Brescia, Italy)

#### Pregnancy in patient with renal lupus

Presenter: E. Gremese (Rome, Italy)

Discussants:

A. Doria (Padua, Italy), M. Khamashta (Dubai, UAE), M. Mosca (Pisa, Italy)

#### Low titers (negative) aPL in obstetric APS

Presenter: L. laccarino (Padua, Italy)

Discussants:

C.B. Chighizola (Milan, Italy), R.A. Levy (Rio de Janeiro, Brazil), J. Salmon (New York, USA)

#### **SATURDAY 28 AUGUST 2021**

#### **Baccarat Room**

#### 08:30-10:00 THE EXPERIENCE OF REGISTRIES

Chairpersons: M. Govoni (Ferrara, Italy), C. Tani (Pisa, Italy)

#### Round Table:

L. Andreoli (Brescia, Italy), C. Chambers (San Diego, USA),

N. Costedoat-Chalumeau (Paris, France), F. Förger (Bern, Switzerland),

I. Giles (London, UK), Y. Meissner (Berlin, Germany), M. Wallenius (Trondheim, Norway)

## DAMAGE BUT NOT REMISSION STATUS IS A PREDICTOR OF ADVERSE PREGNANCY OUTCOME IN LUPUS PREGNANCIES: RESULTS FROM THE PROSPECTIVE GR2 MULTICENTRIC FRENCH STUDY

M. Larosa<sup>1</sup>, G. Guettrot-Imbert<sup>2</sup>, V. Le Guern<sup>2</sup>, E. Lazaro<sup>3</sup>, N. Morel<sup>2</sup>, N. Abisror<sup>2</sup>, C. Morati Hafsaoui<sup>4</sup>, P. Orquevaux<sup>5</sup>, E. Diot<sup>6</sup>, F. Sarrot-Reynauld<sup>7</sup>, A. Doria<sup>1</sup>, A. Molto<sup>2</sup>, C. Deneux Tharaux<sup>2</sup>, N. Costedoat Chalumeau<sup>2</sup>

(<sup>1</sup>Padua, Italy, <sup>2</sup>Paris, France, <sup>3</sup>Bordeaux, France, <sup>4</sup>Annecy, France, <sup>5</sup>Reims, France, <sup>6</sup>Tours, France, <sup>7</sup>Grenoble Alpes, France)

## CAN LOW-DOSE ASPIRIN DURING PREGNANCY PREVENT THE DEVELOPMENT OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH ARTHRITIS? DATA FROM THE P-RHEUM.IT STUDY

D. Lini<sup>1</sup>, M.C. Gerardi<sup>1</sup>, A. Zanetti<sup>2</sup>, G. Carrara<sup>2</sup>, A. Bortoluzzi<sup>2</sup>, F. Crisafulli<sup>1</sup>, M. Filippini<sup>1</sup>, M. Fredi<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, A. Lojacono<sup>1</sup>, L. Moschetti<sup>1</sup>, C. Nalli<sup>1</sup>, S. Panaro<sup>1</sup>, F. Ramazzotto<sup>1</sup>, F. Regola<sup>1</sup>, M. Taglietti<sup>1</sup>, S. Zatti<sup>1</sup>, C.A. Scirè<sup>2,3</sup>, L. Andreoli<sup>1</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup>

(¹Brescia, Italy, ²Milan, Italy, ³Ferrara, Italy)

### PREGNANCY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS A FIRST ANALYSIS OF A EUROPEAN COLLABORATION OF PREGNANCY REGISTRIES

Y. Meissner<sup>1</sup>, N. Costedoat-Chalumeau<sup>2</sup>, F. Förger<sup>3</sup>, D. Goll<sup>1</sup>, A. Molto<sup>2</sup>, R. Özdemir<sup>4</sup>, M. Wallenius<sup>5</sup>, A. Strangfeld<sup>1</sup>, R. Fischer-Betz<sup>6</sup>

(<sup>4</sup>Berlin, Germany, <sup>2</sup>Paris, France, <sup>3</sup>Bern, Switzerland, <sup>4</sup>Duisburg, Germany, <sup>5</sup>Trondheim, Norway, <sup>6</sup>Düsseldorf, Germany)

#### **SATURDAY 28 AUGUST 2021**

Azalea Room

#### 08:30-10:00 GENERAL MANAGEMENT OF PREGNANT WOMEN WITH RHEUMATIC DISEASES

Chairpersons: M. Gerosa (Milan, Italy), C. Zanardini (Brescia, Italy)

#### Nutrition in pregnant patients with rheumatic diseases

M. Cutolo (Genoa, Italy)

#### Mutual gaze and early mother-infant interactions

E. Fazzi (Brescia, Italy)

#### The importance of adjunctive therapies

I. Cetin (Milan, Italy)

### LOW DOSE ASPIRIN USE IN LUPUS PREGNANCY IS ASSOCIATED WITH A REDUCED RISK OF PRE-ECLAMPSIA

I. Haase, M. Schneider, R. Fischer-Betz (Düsseldorf, Germany)

## COMPARISON OF TREATMENTS FOR THE PREVENTION OF FETAL GROWTH RESTRICTION IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

M.L. Urban<sup>1</sup>, A. Bettiol<sup>1</sup>, I. Mattioli<sup>1</sup>, G. Emmi<sup>1</sup>, G. Di Scala<sup>1</sup>, L. Avagliano<sup>2</sup>, N. Lombardi<sup>1</sup>, G. Crescioli<sup>1,3</sup>, G. Virgili<sup>1</sup>, C. Serena<sup>1</sup>, F. Mecacci<sup>1</sup>, C. Ravaldi<sup>1,3</sup>, A. Vannacci<sup>1,3</sup>, E. Silvestri<sup>1</sup>, D. Prisco<sup>1</sup>

(<sup>1</sup>Florence, Italy, <sup>2</sup>Milan, Italy, <sup>3</sup>Prato, Italy)

### DEVELOPING A WEB-BASED PATIENT EDUCATIONAL PROGRAMME ON PREGNANCY AND RHEUMATIC DISEASES

I. R. Nilssen, T.S. Moksnes (*Trondheim, Norway*)

10:00-10:30 Break

#### **SATURDAY 28 AUGUST 2021**

**Baccarat Room** 

#### 10:30-12:00 WHEN THE BABY IS BORN

Chairpersons: R.J.E.M. Dolhain (Rotterdam, The Netherlands), E. Gremese (Rome, Italy)

#### To manage puerperium in patients with rheumatic diseases

I. Haase (Düsseldorf, Germany)

Lactation: YES or NO

B. Bermas (Dallas, USA)

#### The long-term outcome of children

A. Tincani (Brescia, Italy)

### BREASTFEEDING IN WOMEN AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS: RATE, DURATION AND ASSOCIATED FACTORS

V. Orefice, F. Ceccarelli, C. Pirone, P. Galoppi, F.R. Spinelli, C. Alessandri, R. Brunelli, G. Perrone, F. Conti (Rome, Italy)

## VACCINATIONS OF INFANTS BORN TO MOTHERS ON THE INHIBITORS: SAFE ADMINISTRATION OF LIVE-VACCINES GIVEN PER THE NATIONAL IMMUNIZATION PROGRAM

E. Satti, N. Hadwan, S. Al Emadi (Doha, Qatar)

### DEVELOPMENT OF CHILDREN BORN TO MOTHERS WITH RHEUMATIC DISEASE: DATA FROM THE P-RHEUM.IT STUDY

F. Regola<sup>1</sup>, C. Nalli<sup>1</sup>, A. Bortoluzzi<sup>2,3</sup>, G. Carrara<sup>2</sup>, F. Crisafulli<sup>1</sup>, M. Filippini<sup>1</sup>, M. Fredi<sup>1</sup>, M.C. Gerardi<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, D. Lini<sup>1</sup>, A. Lojacono<sup>1</sup>, L. Moschetti<sup>1</sup>, S. Panaro<sup>1</sup>, F. Ramazzotto<sup>1</sup>, C.A. Scirè<sup>2,3</sup>, M. Taglietti<sup>1</sup>, A. Zanetti<sup>2</sup>, S. Zatti<sup>1</sup>, L. Andreoli<sup>1</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup>

(<sup>1</sup>Brescia, Italy, <sup>2</sup>Milan, Italy, <sup>3</sup>Ferrara, Italy)

#### 12:00-12:30 **CLOSING CEREMONY**

F. Förger (Bern, Switzerland), A. Tincani (Brescia, Italy)

### POSTER SESSION 1: COUNSELLING AND PRACTICAL ADVICES BEFORE AND DURING PREGNANCY AND REGARDING PARENTHOOD

#### PO1:01 | THE IMPORTANCE OF PREGNANCY PLANNING IN LUPUS PREGNANCIES

A. Rajendran, A. Eudy, S. Balevic, M. Clowse (Durham, USA)

### PO1:02 | PATIENT SATISFACTION WITH OUR SPECIALIZED CLINICAL PATH FOR WOMEN WITH AN INFLAMMATORY RHEUMATIC DISEASE AND A WISH TO CONCEIVE

H. Wintjes, A.J. van Steensel, M.K. de Vroed, M. Bongenaar, H.T.W. Smeele, A.G.M.G.J. Mulders, R.J.E.M. Dolhain

(Rotterdam, The Netherlands)

### PO1:03 | EFFECTIVENESS OF A MULTIDISCIPLINARY CLINICAL PATHWAY FOR WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR ANTIPHOSPHOLIPID SYNDROME

M. Wind, M. Hendriks, B. van Brussel, J. Eikenboom, C. Allaart, H. Lamb, H.M. Siebelink, M. Ninaber, N. van Geloven, T. Huizinga, T. Rabelink, J. van Lith, M. Sueters, O. Teng (Leiden, The Netherlands)

### PO1:04 | THE DEVELOPMENT OF CLINICAL PATHWAYS FOR CONTROLLING PREGNANCIES IN WOMEN WITH INFLAMMATORY RHEUMATIC DISEASE

I. R. Nilssen, T. S. Moksnes, M. Wallenius (*Trondheim, Norway*)

## PO1:05 | #ANCHIOMAMMA: AN ITALIAN AWARENESS CAMPAIGN ON AUTOIMMUNE DISEASES AND PARENTHOOD. HOW TO COMMUNICATE EFFECTIVELY THE AVAILABLE OPTIONS TO BECOME PARENT DESPITE AN AUTOIMMUNE DISEASE.

L. Faravelli<sup>1</sup>, S. Tonolo<sup>2</sup>, V. Corazza<sup>3</sup>, A. Celano<sup>4</sup> (<sup>1</sup>Milan, Italy, <sup>2</sup>Venice, Italy, <sup>3</sup>Bologna, Italy, <sup>4</sup>Lecce, Italy)

#### PO1:06 | FACTORS INVOLVED IN FAMILY PLANNING FOR WOMEN WITH RHEUMATIC DISEASES

J.E. Compeán-Villegas, L.G. Espinosa-Bañuelos, C.M. Skinner-Taylor, L. Pérez-Barbosa, R.A. Rodríguez-Chávez, A.Y. Lujano-Negrete, R. Moyeda-Martínez, J.A. Cárdenas-de la Garza, D. Á. Galarza-Delgado (Monterrey, Mexico)

### PO1:07 | DOMESTIC VIOLENCE IN PREGNANT AND POSTPARTUM WOMEN WITH RHEUMATIC DISEASES

L.G. Espinosa Banuelos, S.J. Perez-Armendariz, C.M. Skinner-Taylor, L. Perez-Barbosa, M.E. Corral-Trujillo, R.A. Rodriguez-Chavez, A.Y. Lujano-Negrete, R. Moyeda-Martinez, J. A. Cardenas-de la Garza, D. A. Galarza-Delgado (Monterrey, Mexico)

### PO1:08 | HIFU (HIGH INTENSITY FOCUSED ULTRASOUND) FOR THE RESTORATION OF VAGINAL SICCA SYMPTOMS IN PRIMARY SJÖGREN SYNDROME A CASE REPORT

R. Colia, A. Lacerenza, A. Corrado, F. P. Cantatore (Foggia, Italy)

PO1:09 | IT IS NOT JUST ABOUT THE SEX: VIEWPOINTS OF DUTCH ADULT MEN WITH INFLAMMATORY ARTHRITIS REGARDING THE IMPACT OF THE DISEASE ON THEIR SEXUAL HEALTH L.F. Perez, E. Röder, H. Bolt, H. Pastoor, J. Van Exel, R.J.E.M. Dolhain (Rotterdam, The Netherlands)

PO1:10 | THE EFFECT OF PATERNAL EXPOSURE TO IMMUNOSUPPRESSIVE DRUGS ON SEXUAL FUNCTION, REPRODUCTIVE HORMONES, FERTILITY, PREGNANCY AND OFFSPRING OUTCOMES: A SYSTEMATIC REVIEW

L.F. Perez¹, R.J.E.M. Dolhain¹, S. Vorstenbosch², W. Bramer¹, E. Van Puijenbroek³, J. Hazes¹, B. Te Winkel² (¹Rotterdam, The Netherlands, ²S-Hertogenbosch, The Netherlands, ³Groningen, The Netherlands)

### POSTER SESSION 2: MODULATION OF THE IMMUNE SYSTEM BY PREGNANCY (IMMUNOLOGY OF PREGNANCY) AND ASSISTED REPRODUCTION TECHNIQUES

PO2:11 | HEPARIN SIGNIFICANTLY INCREASES CLINICAL PREGNANCY RATES IN PATIENTS WITH REPEATED IMPLANTATION FAILURE

M. Scarrone, S. Bordoli, V. Canti, F. Pasi, L. Quaranta, V. S. Vanni, P. Rovere Querini (Milan, Italy)

PO2:12 | UNEXPLAINED RECURRENT EARLY MISCARRIAGES OR FAILURES UNEXPLAINED RECURRENT IMPLANTATIONS: WHAT ABOUT ANTIBODIES ANTI-NUCLEAR?

N. Abisror, A. Mekinian (*Paris, France*)

PO2:13 | UNEXPLAINED RECURRENT IMPLANTATION FAILURES: PREDICTIVE FACTORS OF PREGNANCY AND THERAPEUTIC MANAGEMENT FROM A FRENCH MULTICENTRE STUDY

K. Kolanska, N. Abisror, A. Mekinian (Paris. France)

PO2:14 | UNEXPLAINED RECURRENT MISCARRIAGES: PREDICTIVE VALUE OF IMMUNE BIOMARKERS AND IMMUNOMODULATORY THERAPIES FOR LIVE BIRTH

K. Kolanska, N. Abisror, A. Mekinian (*Paris, France*)

PO2:15 COAGULATION CASCADE IN THE ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE STUDY ON PLASMA AND PLACENTAS OF WOMEN WITH DIFFERENT SUBSETS OF ANTIPHOSPHOLIPID SYNDROME

E. Bertoldo<sup>1</sup>, V. Lotti<sup>1</sup>, M. Tonello<sup>2</sup>, S. Ugolini<sup>1</sup>, C. Scambi<sup>1</sup>, A. Ruffatti<sup>2</sup>, D. Biasi<sup>1</sup> (<sup>1</sup>Verona, Italy, <sup>2</sup>Padua, Italy)

PO2:16 | ROLE OF PLACENTAL INFLAMMATORY MEDIATORS AND GROWTH FACTORS IN PATIENTS WITH RHEUMATIC DISEASES WITH A FOCUS ON SYSTEMIC SCLEROSIS

F. Motta<sup>1</sup>, V. Codullo<sup>2</sup>, V. Ramoni<sup>4</sup>, S. Cesari<sup>2</sup>, G. Ferrario<sup>2</sup>, G. Fiandrino<sup>2</sup>, F. Beneventi<sup>2</sup>, S. Rampello<sup>3</sup>, H. Johnsson<sup>1</sup>, C. Montecucco<sup>2</sup>, G. Graham<sup>1</sup> (\*Glasgow, UK, \*2Pavia, Italy, \*Bergamo, Italy, \*Lodi, Italy)

#### PO2:17 | LOW LEVELS OF LIPOCALIN-2 IN SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES

T. T. Pedersen, M. Haug, M. Wallenius, M. Høyseter Fenstad (*Trondheim, Norway*)

### PO2:18 | IMMUNE CELL PROFILING USING MASS CYTOMETER IN PREGNANCY WITH RHEUMATIC DISEASES

A. Koido, T. Nakai, A. Nomura, M. Okada (*Tokyo, Japan*)

#### PO2:19 | SEX RATIO OF NEWBORN CHILDREN FROM WOMEN WITH RHEUMATIC DISEASES

M.E. D'Amico, M. Padovan, A. Bortoluzzi, D. Morano, M. Govoni (Ferrara, Italy)

#### PO2:20 | THE ERASMUS MEDICAL CENTRE REPRODUCTIVE RHEUMATOLOGY BIOBANK

M. Bongenaar, H.T.W. Smeele, E. Röder, E. Lubberts, R. J.E.M. Dolhain (Rotterdam, The Netherlands)

### POSTER SESSION 3: INTERACTION BETWEEN PREGNANCY AND DISEASE ACTIVITY IN AUTOIMMUNE RHEUMATIC DISEASES

### PO3:21 | HYDROXYCHLOROQUINE REDUCES THE INCIDENCE OF INTRAUTERINE GROWTH RESTRICTION AND PREECLAMPSIA IN SLE PREGNANT PATIENTS

V. Canti, M. Scarrone, R. De Lorenzo, R. Erra, S. Bordoli, S. Cella, E. Schmit, S. Rosa, M.T. Castiglioni, P. Rovere-Querini (Milan. Italy)

### PO3:22 | ANTIPHOSPHOLIPID ANTIBODIES AND FERTILITY: NO IMPACT ON OVARIAN RESERVE IN PREMENOPAUSAL WOMEN

A. Barinotti, M. Radin, I. Cecchi, S. G. Foddai, E. Rubini, F. Sini, E. Menegatti, D. Roccatello, S. Sciascia (*Turin, Italy*)

### PO3:23 | THE EFFECT OF RHEUMATOID ARTHRITIS AND SPONDILOARTHRITIS ON PREGNANCY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY

F. Pistillo<sup>1</sup>, P. De Sandre<sup>2</sup>, E. Fracassi<sup>1</sup>, G. Scanelli<sup>2</sup>, A. Carletto<sup>1</sup>, A. Hoxha<sup>2</sup> (<sup>1</sup>Verona, Italy, <sup>2</sup>Vicenza, Italy)

### PO3:24 | PREGNANCY IN WOMEN WITH SPONDYLOARTHRITIS: WHO ARE THE PATIENTS AT RISK OF DISEASE FLARE? DATA FROM TWO EUROPEAN CENTERS

F. Crisafulli<sup>1</sup>, R. Cruz-Machado<sup>2</sup>, M.C. Gerardi<sup>1</sup>, S. C. Barreira<sup>2</sup>, P. Martins<sup>2</sup>, M. Filippini<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, D. Lini<sup>1</sup>, C. Nalli<sup>1</sup>, M. Taglietti<sup>1</sup>, A. Lojacono<sup>1</sup>, S. Zatti<sup>1</sup>, C. Zanardini<sup>1</sup>, M. Centeno<sup>2</sup>, C. Araújo<sup>2</sup>, L. Pinto<sup>2</sup>, S. Capela<sup>2</sup>, L. Andreoli<sup>1</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup> (<sup>1</sup>Brescia, Italy, <sup>2</sup>Lisbon, Portugal)

### PO3:25 | REPRODUCTIVE HEALTH OUTCOMES IN WOMEN WITH RHEUMATOID AND PSORIATIC ARTHRITIS

K. M. Murray, L. Moore, P. Gallagher, Y. Alammari, C. O' Brien, C. Brophy, F. Mc Auliffe, D. Veale (Dublin, Ireland)

#### PO3:26 | PREGNANCY AND SHRINKING LUNG SYNDROME: A CASE REPORT

E. Montabone<sup>1</sup>, V. Data<sup>1</sup>, L. Marozio<sup>2</sup>, S. Sciascia<sup>2</sup>, D. Roccatello<sup>2</sup>, R. Carignola<sup>1</sup> (\*Orbassano, Italy, \*2Turin, Italy)

### PO3:27 | CLINICAL COURSE OF UCTD DURING PREGNANCY AND PREGNANCY OUTCOMES: DATA FROM THE P-RHEUM.IT STUDY

F. Crisafulli<sup>1</sup>, L. Andreoli<sup>1</sup>, A. Zanetti<sup>2</sup>, G. Carrara<sup>2</sup>, A. Bortoluzzi<sup>2,3</sup>, M. Filippini<sup>1</sup>, M. Fredi<sup>1</sup>, M.C. Gerardi<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, D. Lini<sup>1</sup>, C. Nalli<sup>1</sup>, M. Taglietti<sup>1</sup>, A. Lojacono<sup>1</sup>, S. Zatti<sup>1</sup>, C. Zanardini<sup>1</sup>, C.A. Scirè<sup>2,3</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup> (<sup>1</sup>Brescia, Italy, <sup>2</sup>Milan, Italy, <sup>3</sup>Ferrara, Italy)

## PO3:28 | RISK OF ADVERSE PREGNANCY OUTCOME IN SLE PATIENTS WITH PRIOR SEVERE ORGAN MANIFESTATION IN JAPAN: A SINGLE-CENTER RETROSPECTIVE ANALYSIS WITH DETAILED DESCRIPTION

T. Nakai, A. Kitada, S. Fukui, M. Okada (*Tokyo, Japan*)

#### PO3:29 | ENHANCED SPD-L1 PREDICTS FLARE IN RA PREGNANCY AND POSTPARTUM

A. Stefanski<sup>1</sup>, K. Eriksson<sup>2</sup>, A. Zbinden<sup>2</sup>, P.M. Villiger<sup>2</sup>, T. Dörner<sup>1</sup>, F. Förger<sup>2</sup> (<sup>1</sup>Berlin, Germany, <sup>2</sup>Bern, Switzerland)

### PO3:30 | MULTIVARIANT PREDICTION OF DISEASE ACTIVITY IN THE THIRD TRIMESTER OF PREGNANCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

N. Martínez Sánchez, N. Galajares Cabada, A. Peralbo Moreno, Á. Robles Marhuenda, M. Muner Hernando, M. De La Calle Fernandez, J.L. Bartha (Madrid. Spain)

### PO3:31 | RATES OF DISEASE FLARES AND ADVERSE PREGNANCY OUTCOMES AMONG PREGNANT WOMEN TREATED WITH THE INHIBITORS FOR INFLAMMATORY ARTHRITIS

S. Troster<sup>1</sup>, C. Sumner<sup>1</sup>, N. Amiri<sup>2</sup>, M. Gamble<sup>3</sup>, V. Pavlova<sup>4</sup>, F. Ouradou<sup>2</sup>, A. Kouroukis<sup>4</sup>, S. Nazari<sup>1</sup> (\*Edmonton, Canada, \*Vancouver, Canada, \*Arva, Canada, \*Hamilton, Canada)

#### PO3:32 | PREGNANCY OUTCOMES IN ADOLESCENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Y. Tissera<sup>1</sup>, V. Savio<sup>1</sup>, P. Alba<sup>1</sup>, M.I. Quaglia<sup>1</sup>, C. Gobbi<sup>1</sup>, J.A. Albiero<sup>1</sup>, M. R. Figueroa<sup>1</sup>, M. Yorio<sup>1</sup>, N. Cucchiaro<sup>2</sup>, M.E. Crespo Espindola<sup>2</sup>, R. Serrano Morales<sup>3</sup>, V. Juarez<sup>2</sup> (\*Cordoba, Argentina, \*Salta, Argentina, \*Rosario, Argentina)

### PO3:33 | SUCCESSFUL FULL-TERM PREGNANCY IN A WOMAN WITH COGAN'S SYNDROME AFTER IN VITRO FERTILIZATION AND EMBRYO TRANSFER

E. Bellis<sup>1</sup>, V.L. Ramoni<sup>2</sup>, F. Brandolino<sup>1</sup>, E. Marasco<sup>1</sup>, S. Monti<sup>1</sup>, C. Montecucco<sup>1</sup> (\*Pavia, Italy, \*2Lodi, Italy)

### PO3:34 | A SYSTEMATIC LITERATURE REVIEW OF DISEASE ACTIVITY DURING AND AFTER PREGNANCY IN FEMALES WITH PSORIATIC ARTHRITIS

Y. Meissner<sup>1</sup>, T. Rudi<sup>1</sup>, R. Fischer-Betz<sup>2</sup>, A. Strangfeld<sup>1</sup> (<sup>1</sup>Berlin, Germany)

#### PO3:35 | PREGNANCY OUTCOME WITH HELLP SYNDROME AND HYPERURICEMIA

P. Altieri, C. Borghi, N. Rizzo, E. R. Cosentino, C. Bentivenga (Bologna, Italy)

PO3:36 | PREGNANCY OUTCOMES IN PORTUGUESE WOMEN WITH SLE: A RETROSPECTIVE STUDY S. Ganhão, F. Aguiar, M. Rodrigues, I. Brito (Porto, Portugal)

### PO3:37 | FOOD INSECURITY AND PERCEIVED STRESS IN PREGNANT AND POSTPARTUM WOMEN WITH RHEUMATIC DISEASES DURING THE COVID-19

L.G. Espinosa Banuelos, P.R. Ancer-Rodriguez, M.G. Herrera-Lopez, L. Perez-Barbosa, C.M. Skinner-Taylor, R.A. Rodriguez-Chavez, A.Y. Lujano-Negrete, R. Moyeda-Martinez, J.A. Cardenas-de la Garza, D.A. Galarza-Delgado (Monterrey, Mexico)

PO3:38 | A PROSPECTIVE COHORT STUDY ON THE SHORT AND LONG-TERM PROGNOSIS INCLUDING PREGNANCY OUTCOMES OF YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN JAPAN. (PLEASURE-J STUDY): PROGRESS REPORT OF PREGNANCY SUBCOHORT.

K. Kaneko, S. Abe, A. Murashima (*Tokyo, Japan*)

POSTER SESSION 4: DRUG MANAGEMENT DURING PREGNANCY AND LACTATION (PAIN MEDICATIONS; CONVENTIONAL AND BIOLOGIC IMMUNOSUPPRESSIVE DRUGS; ANTICOAGULANT/ANTIAGGREGANT DRUGS; PROPHYLACTIC AND ADJUNCT TREATMENT)

PO4:39 | EXPOSURE TO ANTI-THE BIOLOGICS DURING PREGNANCY - UPDATED RESULTS FROM THE JANSSEN PHARMACOVIGILANCE DATABASE

S. Esslinger<sup>1</sup>, M. Otero-Lobato<sup>1</sup>, J. Slater<sup>2</sup>, S. Gabriel<sup>2</sup>, E. Bolshtyansky<sup>2</sup>, M. Higley<sup>2</sup>, A. Geldhof<sup>1</sup> (\*Leiden, The Netherlands, \*2Horsham, UK)

PO4:40 | THE USE OF RITUXIMAB IN THE SECOND TRIMESTER IN A CASE OF REFRACTORY SLE V. Thanopoulou, V. Quick, M. Mouyis (Luton, UK)

PO4:41 | CANAKINUMAB DURING PREGNANCY AND LACTATION: DRUG LEVEL IN MATERNAL AND BABY SERA, UMBILICAL CORD BLOOD AND BREAST MILK – A CASE REPORT

A. Zbinden, K. Eriksson, N. Bosshard, F. Förger (Bern, Switzerland)

PO4:42 | MATERNAL AND FETAL OUTCOMES IN IMMUNE-MEDIATED RHEUMATIC DISORDERS UNDER BIOLOGICAL AGENTS: EXPERIENCE FROM ONE DEPARTMENT

C. Ancuta, R. Chirieac, E. Ancuta (lasi, Romania)

### PO4:43 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DURING PREGNANCY. A NATIONWIDE DRUG UTILIZATION STUDY.

A. Meaidi<sup>1</sup>, L. Mørch<sup>1</sup>, C. Torp-Pedersen<sup>2</sup>, G. Gislason<sup>3</sup>, A. Rom<sup>1,4</sup> (<sup>1</sup>Copenhagen, Denmark, <sup>2</sup>Hillerød, Denmark, <sup>3</sup>Gentofte, Denmark, <sup>4</sup>Odense, Denmark)

### PO4:44 | SAFETY OF ANTI-TNF-A THERAPY DURING PREGNANCY IN RHEUMATIC DISEASES: DATA RELATING TO A SINGLE-CENTER SERIES

E. Zaccara, L. Castelnovo, D. Bompane, A. Tamburello, P. Faggioli, A. Mazzone (Legnano, Italy)

### PO4:45 | THE USE OF BIOLOGIC AGENTS IN THE PERINATAL PERIOD AND DURING PREGNANCY IN WOMEN WITH RHEUMATIC DISEASES: OWN DATA

G. Gridneva, E. Aronova (Moscow. Russia)

### PO4:46 | A CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT IN PREGNANCY TAKING BELIMUMAB

E. Praino, L. Santo (Barletta, Italy)

### POSTER SESSION 5: THE IMPACT OF AUTOANTIBODIES ON FETAL HEALTH, BIOMARKERS OF ADVERSE PREGNANCY OUTCOME AND THE HEALTH CONDITIONS OF THE OFFSPRING

### PO5:47 | OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?

R. Serrano Morales, R. Nieto, S. Porta, K. Roberts, L. Lema, V. Savio, C. Maldini, Y. Tissera, J. A. Albiero, C. Goizueta, V. Lobo, A. Broll, N. Cucchiaro, S. Perez, P. Izaguirre, A. Estevez, A. Avalo, M. Echetverry, V. Bellomio, M.L. Leguizamon, M.N. Antoniol, C. Perandones, C. Pisoni, M.L. De La Torre, M. Garcia, M.S. Velloso, M. Sacnum, H. Berman, P.A. Moreyra, G. Pons Estel (Rosario, Argentina)

#### PO5:48 | COMPARISON OF OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS) AND NON-CRITERIA OBSTETRIC APS (NC-OAPS): A MULTICENTER RETROSPECTIVE STUDY IN CHINA

Y. Sun, J. Zhao, Y. Song, X. Tian, M. Li, X. Zeng (Beijing, China)

### PO5:49 | ANTIPHOSPHOLIPID ANTIBODIES PREVALENCE IN WOMEN WITH LATE PREGNANCY COMPLICATION AND LOW-RISK FOR CHROMOSOMAL ABNORMALITIES

S. Foddai, M. Radin, E. Rubini, I. Cecchi, S. Sciascia, D. Roccatello, E. Menegatti, S. Gaito, G. Orpheu, L. Marozio, A. Barinotti, T. Manetta, G. Mengozzi (*Turin, Italy*)

### PO5:50 | PREGNANCY OUTCOMES IN PATIENTS WITH ANTI-RO/SSA AND ANTIPHOSPHOLIPID ANTIBODIES: DATA FROM THE P-RHEUM.IT STUDY

L. Moschetti<sup>1</sup>, M. Fredi<sup>1</sup>, A. Bortoluzzi<sup>2,3</sup>, G. Carrara<sup>2</sup>, F. Crisafulli<sup>1</sup>, M. Filippini<sup>1</sup>, M.C. Gerardi<sup>1</sup>, R. Gorla<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, D. Lini<sup>1</sup>, A. Lojacono<sup>1</sup>, C. Nalli<sup>1</sup>, S. Panaro<sup>1</sup>, F. Ramazzotto<sup>1</sup>, F. Regola<sup>1</sup>, C.A. Scirè<sup>2,3</sup>, M. Taglietti<sup>1</sup>, A. Zanetti<sup>2</sup>, S. Zatti<sup>1</sup>, L. Andreoli<sup>1</sup>, F. Franceschini<sup>1</sup>, A. Tincani<sup>1</sup> (<sup>1</sup> Brescia, Italy,<sup>2</sup> Milan, Italy,<sup>3</sup> Ferrara, Italy)

### PO5:51 | COMPLEMENT DEPOSITION AS A MEDIATOR OF ANTIPHOSPHOLIPID ANTIBODY INDUCED PREGNANCY MORBIDITY IN SYSTEMIC LUPUS ERYTHEMATOSUS

Z. Xie, J. Zhao, Q. Wang, X. Tian, M. Li, X. Zeng (Beijing, China)

### PO5:52 | LOW PREVALENCE OF SSA (ANTI-RO) AND SSB (ANTI-LA) AUTOANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS WITH A WISH TO CONCEIVE

J. Smeele, L.F. Perez, J.M.J. Cornette, M.W.J. Schreurs, R.J.E.M. Dolhain (Rotterdam, The Netherlands)

### PO5:53 | THE IMPACT OF ANTI-RO ANTIBODIES ON THE PREGNANCY OUTCOME IN RELATION TO MATERNAL DISEASE PRESENTATION: A DESCRIPTIVE ANALYSIS OF 231 PREGNANCIES

E. Satti, N. Hadwan, S. Al Emadi, F. Alam, R. Saleh, O. Alsaed, H. Ashour (Doha, Qatar)

## PO5:54 THE BENEFICIAL EFFECTS OF THERAPY ON OBSTETRICAL OUTCOMES AND PLACENTA'S HISTOLOGY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES SYNDROME IN A SINGLE ITALIAN REFERENCE CENTRE

S. Cella, V. Canti, S. Bordoli, M. Scarrone, N. P. Tenace, R. De Lorenzo, S. Rosa, M.T. Castiglioni, R. Lucianò, P. Rovere Querini (Milan, Italy)

### PO5:55 | NON-CRITERIA OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (NC-OAPS): OUR EXPERIENCE

M.E. D'Amico, M. Padovan, A. Bortoluzzi, D. Morano, M. Govoni (Ferrara, Italy)

### PO5:56 | ADVERSE PREGNANCY OUTCOMES IN ANTIPHOSPHOLIPID ANTIBODY CARRIERS: RESULTS FROM A SPECIALIZED MULTIDISCIPLINARY UNIT

P. Martins, A. Neto, M. Centeno, C. Araújo, L. Pinto, S. Capela (Lisbon, Portugal)

### PO5:57 | PILOT NETWORK ANALYSIS OF NEW AND OLD AUTOANTIBODIES SPECIFICITIES IN CONNECTIVE TISSUE DISEASES PATIENTS WITH PREGNANCY COMPLICATIONS

I. Cecchi, M. Radin, E. Rubini, S. G. Foddai, A. Barinotti, D. Roccatello, S. Sciascia (*Turin, Italy*)

#### PO5:58 | AUDIT OF THE OBSTETRIC OUTCOMES OF ANTIPHOSPHOLIPID SYNDROME

L. Maciejec-Biskup, M. Germani Batacchi, S. Beski, M. Bickerstaff (London, UK)

### PO5:59 | PERINATAL OUTCOMES AND COMPLEMENT LEVELS IN MEXICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME

R.A. Rodriguez Chavez, C. Skinner-Taylor, L. Perez-Barbosa, J.A. Cardenas-De La Garza, G. Figueroa-Parra, R. Moyeda-Martinez, L.G. Espinosa-Banuelos, A.Y. Lujano-Negrete, D.A. Galarza-Delgado (Monterrey, Mexico)

#### PO5:60 | MATERNAL AND FETAL OUTCOMES IN A SJÖGREN'S SYNDROME PATIENT WITH ANTI-RO ANTIBODIES: THE RESULTS OF A TEAMWORK

M. Tamas<sup>1</sup>, D. Vaida-Voevod<sup>1</sup>, T. Turta<sup>1</sup>, G. Cismaru<sup>1</sup>, E. Buzdugan<sup>1</sup>, D. Muresan<sup>1</sup>, S. Rednic<sup>1</sup>, L. Gozar<sup>2</sup>, G. Caracostea<sup>1</sup>

(<sup>1</sup>Cluj-Napcoca, Romania, <sup>2</sup>Targu Mures, Romania)

### PO5:61 | THE FIRST 1000 DAYS OF LIFE AND REPRODUCTIVE DISORDERS IN WOMEN WITH RHEUMATIC DISEASES (RDS)

M. Orlandi, S. Vannuccini, G. Lepri, K. El Aoufy, M. R. Melis, S. Bellando Randone, S. Guiducci, M. Matucci Cerinic, F. Petraglia (Florence, Italy)

### PO5:62 | THE NEUROPSYCHOLOGICAL OUTCOME OF SCHOOL-AGE CHILDREN BORN TO WOMEN WITH INFLAMMATORY ARTHRITIS

C. Nalli<sup>1</sup>, J. Galli<sup>1</sup>, D. Lini<sup>1</sup>, A. Merlini<sup>1</sup>, S. Piantoni<sup>1</sup>, M.G. Lazzaroni<sup>1</sup>, V. Bitsadze<sup>2</sup>, J. Khizroeva<sup>2</sup>, S. Zatti<sup>1</sup>, L. Andreoli<sup>1</sup>, E. Fazzi<sup>1</sup>, F. Franceschini<sup>1</sup>, A. Makatsariya<sup>2</sup>, Y. Shoenfeld<sup>2,3</sup>, A. Tincani<sup>1,2</sup> (\*Brescia, Italy, \*Moscow, Russia, \*Tel Aviv, Israel)

### POSTER SESSION 6: DELIVERY MODE AND OBSTETRIC OUTCOME IN RHEUMATIC DISEASES; THE POST-PARTUM PERIOD

### PO6:63 | MATERNAL AND FETAL OUTCOMES IN PREGNANT WOMEN WITH PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

A. Neto¹, R. Pinheiro Torres¹, H. Donato², F. Mourão¹, J. Branco¹, F. Pimentel-Santos¹ (¹Lisbon, Portugal, ²Coimbra, Portugal)

### PO6:64 | MATERNAL AND FETAL OUTCOMES IN PREGNANT WOMEN WITH JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

A. Silva<sup>1</sup>, M.H. Lourenço<sup>1</sup>, A. Neto<sup>1,2</sup>, F. Pimentel-Santos<sup>1</sup>, I. Silva<sup>1</sup>, A. F. Mourão<sup>1</sup>, H. Donato<sup>3</sup>, M. Costa<sup>1</sup>, J. Cunha Branco<sup>1</sup>

(<sup>1</sup>Lisbon, Portugal, <sup>2</sup>Funchal, Portugal, <sup>3</sup>Coimbra, Portugal)

## PO6:65 COMPARATIVE STUDY OF ADVERSE PERINATAL OUTCOMES AMONG PREGNANTWOMEN WITH OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS) AND NON-CRITERIA OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (NC-OAPS)

N. Baños, A. Castellanos, G. Barilaro, M. Santana, G. Espinosa (Barcelona, Spain)

### PO6:66 | GESTATIONAL AGE OF LABOR AND MATERNAL AND PERINATAL MORBIMORTALITY IN PREGNANT WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

N. Martínez Sánchez, N. Galajares Cabada, A. Peralbo Moreno, Á. Robles Marhuenda, M. Muner Hernando, M. De La Calle Fernandez, J. L. Bartha *(Madrid, Spain)* 

#### PO6:67 | NEW ONSET SYSTEMIC LUPUS ERYTHEMATOSUS IN PREGNANT PATIENTS

V. Savio<sup>1</sup>, P. A. Moreyra<sup>1</sup>, M. I. Quaglia<sup>1</sup>, Y. Tissera<sup>1</sup>, J. A. Albiero<sup>1</sup>, C. Gobbi<sup>1</sup>, N. Cucchiaro<sup>2</sup>, V. Juarez<sup>2</sup>, M.E. Crespo Espindola<sup>2</sup>, R. Serrano Morales<sup>3</sup>

(<sup>1</sup>Cordoba, Argentina, <sup>2</sup>Salta, Argentina, <sup>3</sup>Rosario, Argentina)

### PO6:68 | TRENDS OF PREGNANCY OUTCOMES IN A LARGE ELECTRONIC HEALTH RECORD COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN THE US

A. Barnado, A. Blaske, A. Camai, L. Wheless (Nashville, USA)

### PO6:69 OBSTETRIC OUTCOMES IN YOUNGER WOMEN LESS THAN 21 YEARS OF AGE COMPARED TO WOMEN BETWEEN AGE 21 AND 25 YEARS WITH RHEUMATIC DISEASE

C. Smith<sup>1</sup>, C. Chambers<sup>1</sup>, R. Baer<sup>1,2</sup>, L. Jelliffe-Pawlowski<sup>2</sup>, G. Bandoli<sup>1</sup> (\*La Jolla, USA, \*2San Francisco, USA)

### PO6:70 | ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIDES DURING CHILDBEARING AGE: THERAPY AND PREGNANCY OUTCOMES

E. Bellis¹, V. L. Ramoni², A. Milanesi¹, E. Marasco¹, F. Brandolino¹, S. Monti¹, C. Montecucco¹ (¹Pavia, Italy, ²Lodi, Italy)

#### PO6:71 | PERINATAL OUTCOMES IN MEXICAN WOMEN WITH RHEUMATIC DISEASES

F. Hernandez-Castro, A.Y. Lujano-Negrete, J. Diaz-Angulo, C.M. Skinner-Taylor, L. Perez-Barbosa, J.A. Cardenas-de la Garza, R.A. Rodriguez-Chavez, L.G. Espinosa-Banuelos, R. Moyeda-Martinez, E.S. Barriga-Maldonado, R. Pineda-Sic, G. Figueroa-Parra, D.A. Galarza-Delgado (Monterrey, Mexico)

#### PO6:72 COVID-19 AND PREGNANCY IN RHEUMATIC DISEASE PATIENTS

R.A. Rodriguez Chavez, C. Skinner-Taylor, L. Perez-Barbosa, G. Figueroa-Parra, J. E. Compean-Villegas, L.G. Espinosa-Banuelos, R. Moyeda-Martinez, Y.A. Lujano-Negrete, J.A. Cardenas-de la Garza, D.A. Galarza-Delgado (Monterrey, Mexico)

### PO6:73 | BIRTH DEFECTS AND ADVERSE PERINATAL OUTCOMES IN WOMEN WITH RHEUMATIC DISEASES

R.A. Rodriguez Chavez, G.A. Lopez-Uriarte, L.E. Martinez-de-Villarreal, C. Skinner-Taylor, L. Perez-Barbosa, G. Figueroa-Parra, E.S. Barriga-Maldonado, I. Perez-Onofre, A. Elizondo-Plazas, L.G. Espinosa-Banuelos, R. Moyeda-Martinez, A.Y. Lujano-Negrete, D.A. Galarza-Delgado (Monterrey, Mexico)



### PO6:74 | INDICATIONS FOR CESAREAN SECTION IN MEXICAN WOMEN WITH RHEUMATIC DISEASES: A CROSS SECTIONAL STUDY

A.Y. Lujano-Negrete, C.M. Skinner-Taylor, L. Perez-Barbosa, J.A. Cardenas-de la Garza, F. Hernandez-Castro, R.A. Rodriguez-Chavez, L.G. Espinosa-Banuelos, R. Moyeda-Martinez, D.A. Galarza-Delgado (Monterrey, Mexico)

### PO6:75 | FEAR OF COVID-19 IN POSTPARTUM WOMEN WITH RHEUMATIC DISEASE: A CROSS-SECTIONAL STUDY

L.G. Espinosa Banuelos, M.E. Corral-Trujillo, C.M. Skinner Taylor, L. Perez-Barbosa, R.A. Rodriguez-Chavez, R. Moyeda-Martinez, A.Y. Lujano-Negrete, J.A. Cardenas-de la Garza, D.A. Galarza-Delgado (Monterrey, Mexico)

#### **SCIENTIFIC INFORMATION**

#### **ABSTRACT**

The presenting author of each accepted abstract has to be registered and follow the virtual Congress. The titles and the authors of the accepted abstracts are listed on the final programme and the complete text of each abstract is published on the abstract book (online version). The abstract book is uploaded in the Congress platform, in the Virtual Bag section.

#### **ORAL PRESENTATIONS**

Oral presentations are limited to 7 minutes followed by 3 minutes of discussion.

Participants presenting in oral sessions have pre-recorded their presentation. During the discussion the presenting author will be able to answer live to all the guestions received by the chairs.

#### **E-POSTERS**

All accepted posters are available on a specific section of the Congress platform and every participant can:

- Search a poster using few keywords, such as topic, authors, title, code
- Zoom in/out to see the details
- Send messages or guestions to the authors searching them in the Chat area of the platform.

#### **ON-DEMAND**

All the live sessions will be available on-demand until November 28, 2021. It will be possibile to watch the missed sessions, or the parallel rooms, 24 hours after the end of the live.

#### MEET THE PROFESSOR

The Meet the Professors will take place in a zoom virtual room on Friday August 27 between 07:30-08:15 and will focus on one of the following topics:

- Antiphospholipid antibody syndrome
- Treatment of chronic arthritis
- Systemic lupus erythematosus
- Safety of antirheumatic drugs
- Counseling about reproduction issue in Rheumatology

Those who have registered for one of the Meet the Professor are asked to be connected to the virtual room 15 minutes before the beginning of the meeting in order to be splitted in 5 different breakouts and follow the correct topic. During the meeting all the connected delegates can turn on their camera and microphone in order to have a better interaction and discuss with the key opinion leader.

Please contact the Organizing Secretariat if you have lost the zoom link.

#### **CURBSIDE CONSULTATIONS**

These sessions encourage a spontaneous discussion of a difficult clinical case. The case is presented by a speaker who raises a few key questions. Three experts give their opinion on the best diagnosis/treatment options and discuss the case among themselves as physicians often do in their daily practice (without any slides). The case is not previously known by any of the discussants. The speaker's role is to ensure a lively conversation and cover the various approaches, as well as to involve the audience in the conversation.



#### **SCIENTIFIC INFORMATION**

#### THE GREAT DEBATE SESSIONS

The purpose of the debates is to have an intense discussion on some of the most burning controversies related to a specific topic. The two sides of each debate will be defended by two leading experts in the field, and the discussion will be controlled by a moderator whose role is to ensure that all aspects of the debate are duly discussed, as well as to involve the audience in the conversation.

#### SIR GRANTS



The Italian Society of Rheumatology (SIR) will provide 15 grants to participants selected for oral or poster presentations which have reached a high score and found to be particularly meritorious by the Referees. Only the presenter of a selected abstract will be eligible for the grant and he/she should be a SIR member, younger than 40 years old and in good standing with the membership fees (2021 included).

The grant of € 1000,00 gross will be recognized directly by SIR to the authors of selected abstracts after the Congress. The winners are bound to join the conference and pay the registration fee.

#### **UEMS/EACCME Accreditation**



The 11<sup>th</sup> International Conference on Reproduction, Pregnancy and Rheumatic diseases, Firenze, Italy, 26/08/2021-28/08/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at <a href="https://www.ama-assn.org/education/earn-credit-participation-international-activities">www.ama-assn.org/education/earn-credit-participation-international-activities</a>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

The online platform will track attendance of delegates each day during the Congress. Each participant could only receive the number of credits he/she is entitled to, according to his/her actual participation at the event, and only once he/she has completed the evaluation form. The process and detailed information will be sent by the Organizing Secretariat after the Congress.

#### **CME PROVIDER**



AIM Education - Provider n. 93 Via G. Ripamonti, 129 - 20141 Milan, Italy Ph. +39 02 56601.1 - Fax +39 02 70048585 cme@aimgroup.eu - www.aimeducation.it



#### **GENERAL INFORMATION**

#### ORGANIZING SECRETARIAT

www.rheumapreg2021.com



AIM Group International - Milan Office Via G. Ripamonti, 129 - 20141 Milan, Italy Ph. +39 0256601.1 - Fax. +39 0270048578 info@rheumapreg2021.com

#### CONGRESS PLATFORM AND VIRTUAL ACCESS

The Congress platform is available at the following link: https://rheumapreg2021.livebit.it/

Participants have received an email with all the details to access the platform.

Once clicked on the link above, it's necessary to select "ACCESS CODE" and then insert the personal code received by email. Then, fill in the requested information and set username and password. Please be sure to click on the button YES for using the chat function or you will not be able to chat with other colleagues and speakers. After your first access, you will be able to LOGIN by simply reporting the username and password that you have set before.

In case that should you need assistance please click the headphones image. Our technician will help you through a live chat.

#### VIRTUAL REGISTRATION DESK

The virtual registration desk will be available during the following days:

#### ATTENDANCE CERTIFICATES

The certificate of attendance will be available after completing the online customer satisfaction together with the EACCME participant's evaluation form. The process will take no more than 5 minutes and more information will be sent on Tuesday 31st August.

#### **OPENING CEREMONY**

The Opening Ceremony of the Congress will be held on August 26 at 19:00 in the Baccarat Room.

#### TIMETABLE

All schedules refer to the Central European Time Zone (GMT+1) but, on the Congress platform (TIMETABLE section), you will be able to select your time zone and the schedule will automatically change.



#### **GENERAL INFORMATION**

#### **VIRTUAL CONGRESS BAG**

In the virtual bag you will find the final programme, the abstract book and sponsored documents.

#### **EXHIBITION**

A virtual exhibition of pharmaceutical companies is available on the event platform clicking on the menu Sponsor. Each booth will have different areas that could be clicked, with the possibility to download documents and watch a video. Each delegate could also contact the company staff and visit their website.

#### **CHAT**

In this menu each delegate could upload his/her photo and add some personal details in order to chat with other colleagues. On the right side you can search the online users and contact them privately.

#### **PRIVACY POLICY**

The information on the processing of personal data in accordance with the European Regulation no. 679 of 2016 is available in the Congress website.

#### **REGISTRATION (ON-DEMAND ONLY)**

22% Italian VAT included when due

	from 17 August to September 30
Virtual Delegate (only on-demand)	€ 100,00

The registration fee is available only for new registrations with an access to the virtual platform after the live Congress. All on-demand delegates will be able to obtain the CME certificate because the online platform will track attendance of delegates in each session.

#### Virtual registration fee (on-demand only) includes:

- Admission to the on-demand scientific sessions
- Virtual Congress bag with complete meeting materials
- · Certificate of attendance
- F-Poster area
- On-demand contents until the end of November 2021.

#### CONFIRMATION OF REGISTRATION

An invoice will be issued as written confirmation of your registration by the Organizing Secretariat.

#### PAYMENT

- By Credit Card: All major credit cards are accepted (American Express, VISA, Eurocard/Master Card)
- By Bank Transfer: Please note your registration will not be confirmed until full payment is received.

Please send us copy of the bank transfer to: <a href="mailto:info@rheumapreg2021.com">info@rheumapreg2021.com</a>. Kindly report on the bank transfer RHEUMAPREG2021 and Name/ Surname of the participant.



#### **THURSDAY 26 AUGUST**

#### **Baccarat Room**

### 17:30-19:00 UCB SATELLITE SYMPOSIUM HOPE FOR THE FUTURE: HOW FAR HAVE WE COME AND WHERE ARE WE GOING?

Chairperson: A. Tincani (Brescia, Italy)

Speakers: L. Andreoli (Brescia, Italy), C. Nelson-Piercy (London, UK), N. Wulffraat (Utrecht, The Netherlands)



# Hope for the Future: How Far Have We Come and Where Are We Going?

Thursday, 26th August 2021

17:30-19:00 CET



#### SYMPOSIUM OBJECTIVES

- To reflect on the progress made, and challenge the remaining unmet needs in multidisciplinary treatment of women with chronic rheumatic diseases (CRDs)
- To challenge the status quo and analyse the latest evidence around the unmet needs still faced by women with CRDs
- Welcome and Introduction Prof. Angela Tincani
- Progress in Pregnancy? An Obstetric Physician's Reflection
   Prof. Catherine Nelson-Piercy
- Can I Get Pregnant? Prof. Laura Andreoli
- > Flares During Pregnancy: What Do We Do and What is the Evidence? Prof. Laura Andreoli
- Do I Have to Compromise to Protect My Baby? Prof. Nico Wulffragt
- > Wrap-Up and Summary Prof. Catherine Nelson-Piercy
- > Question and Answer Discussion Moderated by Prof. Angela Tincani



Prof. Angela Tincani (Chairperson) University of Brescia, Brescia General Hospital, Italy



Prof. Catherine Nelson-Piercy
Imperial College Healthcare NHS
Trust and Guy's and St. Thomas'
NHS Foundation Trust, UK



Prof. Laura Andreoli University of Brescia, Brescia General Hospital, Italy



Prof. Nico Wulffraat
University Medical Center, Utrecht,
The Netherlands

Please click <u>here</u> for Speaker Biographies.





### **ACKNOWLEDGMENTS**

#### **PLATINUM SPONSOR**



#### **SPONSORS**







